Foghorn Therapeutics Files 8-K

Ticker: FHTX · Form: 8-K · Filed: Feb 3, 2025 · CIK: 1822462

Foghorn Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyFoghorn Therapeutics Inc. (FHTX)
Form Type8-K
Filed DateFeb 3, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, reporting, regulation-fd

TL;DR

Foghorn Therapeutics filed a routine 8-K, no major news.

AI Summary

Foghorn Therapeutics Inc. filed an 8-K on February 3, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates standard corporate reporting by Foghorn Therapeutics, but lacks details on specific material events or financial performance.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting purposes and does not disclose any new material information that would immediately impact risk.

Key Players & Entities

  • Foghorn Therapeutics Inc. (company) — Registrant
  • 0001822462 (company) — Central Index Key
  • 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
  • 02139 (company) — ZIP Code
  • 617-586-3100 (company) — Business Phone

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and Financial Statements and Exhibits.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is February 3, 2025.

What is the company's principal executive office address?

The principal executive offices are located at 500 Technology Square, Suite 700, Cambridge, MA 02139.

In which state was Foghorn Therapeutics Inc. incorporated?

Foghorn Therapeutics Inc. was incorporated in Delaware.

What is the Standard Industrial Classification code for Foghorn Therapeutics Inc.?

The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 491 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-02-03 07:00:59

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share FHTX The Nasdaq Glo

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Foghorn Therapeutics Inc. (the "Company") is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a presentation dated February 2025, which the Company intends to use in meetings with or presentations to investors. The information in this Item 7.01 (including Exhibits 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Investor Presentation dated February 2025

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FOGHORN THERAPEUTICS INC. By: /s/ Kristian Humer Kristian Humer Chief Financial Officer Date: February 3, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.